Cargando…
The novel dual PI3K/mTOR inhibitor NVP-BGT226 displays cytotoxic activity in both normoxic and hypoxic hepatocarcinoma cells
Hepatocellular carcinoma (HCC) is one of the most common lethal human malignancies worldwide and its advanced status is frequently resistant to conventional chemotherapeutic agents and radiation. We evaluated the cytotoxic effect of the orally bioavailable dual PI3K/mTOR inhibitor, NVP-BGT226, on a...
Autores principales: | Simioni, Carolina, Cani, Alice, Martelli, Alberto M., Zauli, Giorgio, Alameen, Ayman A.M., Ultimo, Simona, Tabellini, Giovanna, McCubrey, James A., Capitani, Silvano, Neri, Luca M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4627298/ https://www.ncbi.nlm.nih.gov/pubmed/26003166 |
Ejemplares similares
-
Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia
por: Cani, Alice, et al.
Publicado: (2015) -
Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation
por: Simioni, Carolina, et al.
Publicado: (2014) -
The AKT Inhibitor MK-2206 is Cytotoxic in Hepatocarcinoma Cells Displaying Hyperphosphorylated AKT-1 and Synergizes with Conventional Chemotherapy
por: Simioni, Carolina, et al.
Publicado: (2013) -
Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia
por: Simioni, Carolina, et al.
Publicado: (2016) -
Healthy CD4(+) T lymphocytes are not affected by targeted therapies against the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia
por: Alameen, Ayman A.M., et al.
Publicado: (2016)